High expression of pdl-1 in patients with triple negative breast cancer with residual tumor burden after neoadjuvant chemotherapy.

被引：1
|
作者：
Oner, Gizem [1 ]
Onder, Semen [1 ]
Karatay, Huseyin [1 ]
Tukenmez, Mustafa [1 ]
Muslumanoglu, Mahmut [1 ]
Igci, Abdullah [1 ]
Dinccag, Ahmet [1 ]
Ozmen, Vahit [1 ]
Aydiner, Adnan [1 ]
Yavuz, Ekrem [1 ]
Cabioglu, Neslihan [1 ]
机构：
[1] Istanbul Univ, Istanbul, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e24136
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e24136
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy.
    Symmans, W.
    Peintinger, F.
    Hatzis, C.
    Kuerer, H.
    Valero, V.
    Hennessy, B.
    Green, M.
    Singletary, E.
    Hortobagyi, G.
    Pusztai, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 12S - 12S
  • [22] Circulating tumor DNA fraction correlates with residual cancer burden postneoadjuvant chemotherapy in triple negative breast cancer patients
    Shan, Naing Lin
    Gould, Billie
    Blenman, Kim
    Foldi, Julia
    Du, Pan
    Zhang, Frank
    Walsh, Myles
    Pusztai, Lajos
    CANCER RESEARCH, 2024, 84 (09)
  • [23] Tumor Infiltrating Lymphocytes (TILs) in triple-negative breast cancer: High Immunoscore is associated with pathological CR in patients receiving neoadjuvant chemotherapy.
    Rapoport, Bernardo
    Nayler, Simon
    Galon, Jerome
    Mlecnik, T.
    Smit, Teresa
    Barnard-Tidy, Jacqui
    Fugon, Aurelie
    Martel, Marine
    Anderson, Ronald
    Benn, Carol
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [24] Prognostic Impact of Residual Disease After Neoadjuvant Chemotherapy in 648 Patients with Triple-negative Breast Cancer
    Kern, Peter
    Von Minckwitz, Gunter
    Puetter, Carolin
    Pavlidou, Sofia
    Flach, Annika
    Kimmig, Rainer
    Rezai, Mahdi
    ANTICANCER RESEARCH, 2015, 35 (10) : 5479 - 5484
  • [25] Prospective genomic and PD-L1 profiling of patients with residual triple negative breast cancer after neoadjuvant chemotherapy
    Irie, Hanna Yoko
    Schmidt, Paul
    Port, Elisa
    Berger, Natalie
    Klein, Paula
    Kinoshita, Yayoi
    Soto, Alan
    Pisapati, Kereeti
    Couri, Ronald
    Kolodka, Olivia
    Arib, Hanane
    Sebra, Robert
    Donovan, Michael J.
    CANCER RESEARCH, 2020, 80 (04)
  • [26] Monitoring of Triple Negative Breast Cancer After Neoadjuvant Chemotherapy
    Aldrich, Jeffrey
    Canning, Madison
    Bhave, Manali
    CLINICAL BREAST CANCER, 2023, 23 (08) : 832 - 834
  • [27] Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
    Li, Zhijun
    Han, Yiqun
    Wang, Jiayu
    Xu, Binghe
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (02):
  • [28] THE GENE EXPRESSION PROFILE OF TRIPLE-NEGATIVE BREAST CANCER AFTER NEOADJUVANT CHEMOTHERAPY
    Philipovskiy, A.
    Gaur, S.
    Chambers, K.
    Gamez, R.
    McCallum, R.
    Kirken, R.
    Aguilera, R.
    Roy, S.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2021, 69 (02) : 440 - 440
  • [29] Response to neoadjuvant chemotherapy in patients with triple negative breast cancer
    Abe, E.
    Hayashi, N.
    Yoshida, A.
    Hamaoka, T.
    Yagata, H.
    Tsugawa, K.
    Tsunoda-Shimizu, H.
    Suzuki, K.
    Nakamura, S.
    CANCER RESEARCH, 2009, 69 (02) : 367S - 367S
  • [30] Neoadjuvant chemotherapy regimens for triple negative breast cancer patients
    Gigolaeva, L.
    Krivorotko, P.
    Zhiltsova, E.
    Dashyan, G.
    Chadjimatova, S.
    Pesotckiy, R.
    Emelyanov, A.
    Semiglazov, V.
    BREAST, 2019, 44 : S70 - S70
12345